TO STUDY PALLIATION OF SYMPTOMS BY A HYPOFRACTIONATED RADIOTHERAPY SCHEDULE IN ADVANCED INOPERABLE SQUAMOUS CELL CARCINOMAS OF THE ORAL CAVITY
DOI:
https://doi.org/10.22159/ajpcr.2023.v16i12.49854Keywords:
European organization for research and treatment of cancer, Quality of life questionnaire, Eastern cooperative oncology group, Physical functioning, role functioning, Emotional functioning, Cognitive functioning, Social functioningAbstract
Objective: The aim of the study was to study palliation of symptoms and improvements in quality of life (QoL) in inoperable squamous cell cancers of the oral cavity with a hypofractionated radiotherapy schedule.
Methods: It is a prospective and observational study in patients with locally advanced squamous cell cancers of the oral cavity attending the outpatient clinic who have been deemed inoperable after discussion in a multidisciplinary team were considered. The data was tested using Friedman’s test for the significance in QoL.
Results: All of the functional scales were found significant in this study with physical functioning, emotional functioning and cognitive functioning (CF) being significant at 1% alpha level while role functioning (RF) and social functioning (SF) are significant at 5% alpha level. RF was assessed based on the capabilities of the patient to finish daily activities. The median score remained at 33 but the interquartile range (IQR) was showing an increasing trend. Both pain and head-and-neck specific pain had significantly reduced over time. Fatigue had shown a constant reduction during radiation and during the first follow-up as well. The increase in nausea, vomiting, and constipation during radiation can be attributed to the use of morphine during radiation for pain control and as an effect of radiation itself. There was weight loss during radiation which improved during subsequent follow-up visits.
Conclusions: In patients diagnosed with inoperable oral cavity cancer, hypofractionated radiotherapy delivering 50 Gy in 20 fractions over 4 weeks is a well-tolerated and safe regimen. In our study, statistically significant QoL improvement in global health score, SF, and CF lasting for a minimum of 6 weeks was attained after completion of treatment with this regimen.
Downloads
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49. doi: 10.3322/caac.21660
Borse V, Konwar AN, Buragohain P. Oral cancer diagnosis and perspectives in India. Sens Int 2020;1:100046.
Petti S. Lifestyle risk factors for oral cancer. Oral Oncol 2009;45:340-50.
Final Recommendation Statement: Oral Cancer: Screening - US Preventive Services Task Force. Available from: https://www.uspreventiveservicestaskforce.org/uspstf/document/RecommendationStatementFinal/oral-cancer-screening
[Last accessed on 2016 Jul 17].
Hodson DI, Bruera E, Eapen L, Groome P, Keane T, Larsson S, et al. The role of palliative radiotherapy in advanced head and neck cancer. Can J Oncol 1996;6 Suppl:54-60.
Fowler JF. 21 years of biologically effective dose. Br J Radiol 2010;83:554-68.
Nahum AE. The radiobiology of hypofractionation. Clin Oncol 2015;27:260-9.
Maciejewski B, Withers HR, Taylor JM, Hliniak A. Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: Tumor dose-response and repopulation. Int J Radiat Oncol Biol Phys 1989;16:831-43.
Hall EJ. Radiobiology for the Radiologist. Philadelphia, PA: Lippincott; 2000. Available from: ??? [Last accessed on 2016 Feb 23].
Pajonk F, Vlashi E, McBride WH. Radiation resistance of cancer stem cells: The 4 R‘s of radiobiology revisited. Stem Cells 2010;28:639-48.
Mohanti BK, Umapathy H, Bahadur S, Thakar A, Pathy S. Short course palliative radiotherapy of 20 Gy 5 in fractions for advanced and incurable head and neck cancer: AIIMS study. Radiother Oncol 2004;71:275-80.
Agarwal JP, Nemade B, Murthy V, Ghosh-Laskar S, Budrukkar A, Gupta T, et al. Hypofractionated, palliative radiotherapy for advanced head and neck cancer. Radiother Oncol 2008;89:51-56.
Fortin B, Khaouam N, Filion E, Nguyen-Tan PF, Bujold A, Lambert L. Palliative radiation therapy for advanced head and neck carcinomas A phase 2 study. Int J Radiat Oncol Biol Phys 2016;95:647-53.
Murthy V, Kumar DP, Budrukkar A, Gupta T, Ghosh-Laskar S, Agarwal J. Twice-weekly palliative radiotherapy for locally very advanced head and neck cancers. Indian J Cancer 2016;53: 138-41.
Lok BH, Jiang G, Gutiontov S, Lanning RM, Sridhara S, Sherman EJ, et al. Palliative head and neck radio- therapy with the RTOG 8502 regimen for incurable primary or met- astatic cancers. Oral Oncol 2015;51:957-62.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
Scott NW, Fayers PM, Bottomley A, Aaronson NK, de Graeff A, Groenvold M, et al. Comparing translations of the EORTC
QLQ-C30 using differential item functioning analyses. Qual Life Res 2006;15:1103-15; discussion 1117-20. doi: 10.1007/s11136-006-
-x. PMID: 16900290
Joshi P, Dutta S, Chaturvedi P, Nair S. Head and neck cancers in developing countries. Rambam Maimonides Med J 2014;5:e0009.
Published
How to Cite
Issue
Section
Copyright (c) 2023 G.Sri Rama Murthy
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
